Prothena to Receive $80 Million from Bristol Myers Squibb for Exclusive Global License to PRX019; Phase 1 Clinical Trial to Begin in 2024
Portfolio Pulse from Benzinga Newsdesk
Prothena will receive $80 million from Bristol Myers Squibb for an exclusive global license to PRX019. A Phase 1 clinical trial is set to begin in 2024.

May 28, 2024 | 8:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol Myers Squibb is investing $80 million for an exclusive global license to Prothena's PRX019, with a Phase 1 clinical trial starting in 2024.
Bristol Myers Squibb's $80 million investment in PRX019 shows their commitment to expanding their drug portfolio, which could positively impact their stock price by demonstrating strategic growth and innovation.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Prothena will receive $80 million from Bristol Myers Squibb for an exclusive global license to PRX019, with a Phase 1 clinical trial starting in 2024.
The $80 million payment from Bristol Myers Squibb provides significant funding for Prothena, which can positively impact its financial stability and stock price. The initiation of a Phase 1 clinical trial in 2024 also indicates progress in their drug development pipeline.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100